Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.97 |
| ▸ | LTA4H | P09960 | 6/20 | 0.85 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.71 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.71 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.71 |
| ▸ | HRH1 | P35367 | 2/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | ACHE | P22303 | 1/20 | 0.68 |
| ▸ | RAD52 | P43351 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8637452 | 0.98 | HRH3 (1.00) | HRH3LTA4HPSMB1PSMB5PSMB2 | |
| SCHEMBL8640984 | 0.95 | HRH3 (0.89) | HRH3LTA4HPSMB1PSMB5PSMB2 | |
| SCHEMBL7398931 | 0.93 | HRH3 (0.89) | HRH3LTA4HPSMB1PSMB5PSMB2 | |
| SCHEMBL7140970 | 0.92 | LTA4H (1.00) | HRH3LTA4HPSMB1PSMB5PSMB2 | |
| Hydrochloric Acid SCHEMBL7397621 | 0.91 | HRH3 (0.86) | HRH3LTA4HPSMB1PSMB5PSMB2 | |
| SCHEMBL7141103 | 0.91 | LTA4H (1.00) | HRH3LTA4HPSMB1PSMB5PSMB2 | |
| SCHEMBL7133844 | 0.91 | LTA4H (1.00) | HRH3LTA4HPSMB1PSMB5PSMB2 | |
| SCHEMBL1387394 | 0.88 | HRH3 (0.80) | HRH3LTA4HPSMB1PSMB5PSMB2 | |
| SCHEMBL4689454 | 0.88 | KDM4E (0.86) | HRH3LTA4HHRH1KCNH2NPC1 | |
| SCHEMBL492205 | 0.87 | HRH3 (0.84) | HRH3LTA4HHRH1KCNH2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506876-B1 | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use | G.D. SEARLE & CO. | 2003-01-14 | — | — | US | disclosed |
| EP-0804427-B1 | LTA4 HYDROLASE INHIBITORS | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1221441-A2 | LTA4 Hydrolase inhibitors | G.D. SEARLE & CO. (US) | 2002-07-10 | — | — | EP | disclosed |
| US-5723492-A | LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use | G.D. SEARLE & CO. (US) | 1998-03-03 | — | — | US | disclosed |
| US-5719306-A | ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0804427-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0786992-A2 | LTA 4? HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1997-08-06 | — | — | EP | disclosed |
| US-5585492-A | USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES WHICH ARE MEDIATED BY LTB4 PRODUCTION, SUCH AS PSORIASIS, ULCERATIVE COLITIS, IRRITABLE BOWEL DISEASE AND ASTHMA | G. D. SEARLE & CO. (US) | 1996-12-17 | — | — | US | disclosed |
| WO-1996010999-A2 | LTA4 HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | disclosed |
| WO-1996011192-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | disclosed |